RxDoctor Payments Data

Fatima Eidy, PA

Physician Assistant · Dearborn, MINPI 1780193748

Payments from drug & device makers

$7,123in general payments, 2019–2025

Across 409 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$663
  • Lilly USA, LLC$646
  • Ironwood Pharmaceuticals, Inc$580
  • Amgen$450
  • Corcept Therapeutics$433
  • AstraZeneca$422
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$7,111100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,123 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$3,342
Medicare patients
19
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$41,515
LinzessLinaclotide48$33,208
MounjaroTirzepatide22$22,318
TrulicityDulaglutide22$21,304
XareltoRivaroxaban19$18,312
Xigduo XrDapaglifloz Propaned/Metformin19$17,101
JardianceEmpagliflozin16$16,703
Synjardy XrEmpagliflozin/Metformin Hcl16$13,173
JanuviaSitagliptin Phosphate20$12,625
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,868
MyrbetriqMirabegron13$6,368
InvokametCanagliflozin/Metformin Hcl11$5,823
SymbicortBudesonide/Formoterol Fumarate16$3,745
Diclofenac Sodium57$1,680
Albuterol Sulfate HfaAlbuterol Sulfate61$1,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$422$45,25976 claims
Lilly USA, LLCMounjaro, Trulicity$646$43,62244 claims
AbbVieLinzess$410$33,20848 claims
Boehringer IngelheimJardiance, Synjardy Xr$137$29,87632 claims
Johnson & JohnsonXarelto, Invokamet$381$24,13530 claims
MerckJanuvia$38$12,62520 claims
GSKTrelegy Ellipta$298$11,86818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →